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Background:  TV-1380  (AlbuChE)  is  a novel  recombinant  fusion  protein  of  mutated  butyrylcholinesterase
(BChE)  that  has increased  catalytic  efﬁciency  for cocaine  metabolism  compared  to  wild-type  BChE.
Methods:  Intra-muscular  injections  of  TV-1380  (150  mg  or 300 mg)  or placebo  were  administered  once
weekly  to participants  (n =  66–69  per  group)  in  a randomized,  double-blind  study  to  evaluate  the  ability
of  TV-1380  to facilitate  abstinence  in  treatment-seeking,  cocaine-dependent  individuals.  The  primary
endpoint  was  the  proportion  of participants  achieving  abstinence  from  cocaine  during  the  last  three
weeks  of  the  12  week  treatment  phase,  based  on  daily  self-report  of “no  use”  conﬁrmed  by urine  testing.
Results:  Although  there  were  no  signiﬁcant  differences  between  the  TV-1380  treatment  groups  and
placebo  for  the  primary  endpoint,  6% of  participants  in  the  150  mg  and  300 mg  TV-1380  groups  and
no  participants  in the  placebo  group  achieved  abstinence.  For  the  only  declared  secondary  endpoint,
there  was  a  dose-dependent  increase  in  the  group  mean  percentage  of  urine  samples  testing  negative
for  cocaine  metabolites  during  weeks  5–12 (8.1%  and  14.6%  for the  150 mg  and  300 mg  TV-1380  groups,
respectively,  compared  to  4.7%  for the  placebo  group;  p = 0.0056  for 300  mg  vs.  placebo).  No  meaningful
differences  in  adverse  events  were  seen  between  treatment  groups.
Conclusions:  While  the apparent  reduction  in  cocaine  use  may  be  of insufﬁcient  magnitude  to justify
further  trials  of TV-1380  in  cocaine  dependence,  the results  argue  for  development  of improved  enzymes
with  greater  catalytic  activity.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. IntroductionA report by the United Nations Drug Control program (UNDCP)
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∗ Corresponding author at: Research and Scientiﬁc Affairs, Teva Pharmaceuticals
esearch and Development, 11100 Nall Avenue, Overland Park, KS 66047, USA.
E-mail addresses: ygilgun@gmail.com (Y. Gilgun-Sherki), rom.eliaz@teva.co.il
R.E. Eliaz), DMCCANN@NIH.GOV (D.J. McCann), pippa.loupe@tevapharm.com
P.S. Loupe), eli.eyal@teva.co.il (E. Eyal), kathleen.blatt@tevapharm.com (K. Blatt),
rit.cohen-barak@teva.co.il (O. Cohen-Barak), Hussein.Hallak@teva.co.il
H. Hallak), nchiang@nida.nih.gov (N. Chiang), shwe.gyaw@nih.gov (S. Gyaw).
ttp://dx.doi.org/10.1016/j.drugalcdep.2016.05.019
376-8716/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
million people, roughly 0.3–0.4% of the global population between
15 and 64 years of age. In the last decade, cocaine use has only
slightly declined in North America, has stabilized in Europe, and
has increased in Australia, Asia, Africa and some countries in
South America, as new cocaine markets have emerged (UNDCP
2012 report). These epidemiological data reveal a growing medical
need. Cognitive behavioral therapy and contingency management
are the current treatments of choice for cocaine dependence
(Farronato et al., 2013), but many patients fail to achieve mean-
ingful improvement, and there is a need for pharmaceutical
interventions (Simpson et al., 1999).
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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One potential pharmaceutical approach to treatment is the
dministration of a cocaine-metabolizing enzyme that quickly
egrades cocaine in the circulatory system and prevents or attenu-
tes its CNS actions. Human butrylcoholinesterase (BChE) has been
onsidered for treating cocaine overdose; however, its pharmacoki-
etic (PK) properties (both in terms of enzyme half-life and catalytic
ctivity) appear inadequate for the treatment of cocaine depen-
ence (Xie et al., 1999; Jenkins et al., 2002). These PK properties
ave been improved in TV-1380, a fusion protein of mutant BChE
nd human serum albumin (HSA) that was developed to address
ild-type BChE limitations (Gao et al., 2008). The terminal elim-
nation half-life (t1/2) of TV-1380 is approximately 2–3 days and
ultiple once-weekly doses of TV-1380 resulted in very limited
ccumulation of TV-1380 as would be expected with this elimi-
ation half-life. Exposure to the TV-1380 after single and multiple
osing was dose proportional at 50–300 mg  dose range (Cohen-
arak et al., 2015).
In rodents (Brimijoin et al., 2008) and monkeys (Schindler et al.,
013), pretreatment with TV-1380 greatly accelerated cocaine
etabolism. TV-1380 attenuated the toxic effects of cocaine
including lethality) and blocked the ability of cocaine to stimu-
ate cocaine-seeking behavior in rats (Brimijoin et al., 2008). It also
ecreased cocaine self-administration and blocked multiple phar-
acological actions of cocaine in monkeys (Schindler et al., 2013).
n previous phase 1 studies, single and multiple administrations of
V-1380, at intramuscular (IM) doses ranging from 0.5 to 300 mg,
ere shown to be safe and well tolerated (Cohen-Barak et al., 2015;
hram et al., 2015). A PK assessment indicated that there was  a
ose-proportional increase in systemic exposure, and there was
 direct relationship between ex vivo cocaine hydrolysis and TV-
380 serum concentrations (Cohen-Barak et al., 2015). In addition, a
00 mg  dose of TV-1380 was found to substantially increase cocaine
learance in healthy cocaine users (Shram et al., 2015).
The present study employed objective and self-report measures
f cocaine use to evaluate the ability of TV-1380 to safely and effec-
ively increase abstinence in treatment-seeking individuals with
ocaine dependence. It also assessed whether the administration of
V-1380 leads to an increased percentage of urine samples testing
egative for cocaine metabolites.
. Materials and methods
.1. Study design
This was a 12-week, randomized, double-blind, placebo-
ontrolled, parallel-group study conducted at 19 sites in the
nited States and Spain. Institutional review boards at each study
ite approved the protocol and all participants provided written
nformed consent. The trial was conducted in accordance with the
eclaration of Helsinki and ethical principles of Good Clinical Prac-
ice, according to the ICH Harmonized Tripartite Guideline, and was
egistered at Clinicaltrials.gov (NCT01887366).
Subjects participated in a two-week screening period, a 12-week
reatment phase, and a four-week follow-up period that concluded
ith an end-of-study visit in week 16. During the screening period,
omprehensive medical and psychiatric assessments were per-
ormed to determine if subjects met  enrollment criteria. During
ach screening visit, urine samples were collected and assayed
n-site for the presence of cocaine’s primary metabolite, benzoylec-
onine (BE). As part of immunogenicity assessments evaluating
he effects of TV-1380 on endogenous BChE and acethycholine
sterase (AChE), plasma samples were collected to assess baseline
nzyme activity. If the subjects met  screening criteria, they were
andomly assigned to receive treatment (one IM injection every
eek for 12 weeks) with placebo or TV-1380 at a dosage of 150l Dependence 166 (2016) 13–20
or 300 mg/injection in a 1:1:1 ratio. Randomization was performed
using interactive response technology, and a minimization algo-
rithm employing the Pocock and Simon Biased Coin methodology
was used to balance the following covariates: alcohol dependence
(yes/no, as determined by the Structured Clinical Interview for
DSM-IV Axis I Disorders, First et al., 2002), primary route of cocaine
administration, BE-positivity or -negativity of last urine sample
obtained prior to randomization, and country.
During the 12-week treatment period, participants came to the
clinic for three visits per week. During each visit, participant self-
report data on cocaine use since the previous visit during the prior
week was collected using the timeline follow back (TLFB) proce-
dure (Robinson et al., 2014). Urine samples were also collected
during each visit for quantitative BE and ecgonine methyl ester
(EME) assays using a validated method (Shram et al., 2015). Pre-
dose and post-dose blood samples were collected in weeks 1, 4,
8 and 12 for TV-1380 PK analyses. In addition to weekly injec-
tions of investigational product, all subjects received once weekly,
individual, 1-h cognitive behavioral therapy sessions guided by the
National Institute on Drug Abuse treatment manual entitled “A cog-
nitive behavioral approach: Treating cocaine addiction” (Carroll,
1998) during the treatment period. Participant reports of adverse
events (AEs) were collected during each visit, vital signs were mon-
itored on a weekly basis, and blood/urine samples were collected
every four weeks for the purpose of monitoring clinical laboratory
parameters. In addition, numerous assessments were conducted
during screening and treatment to evaluate changes in exploratory
endpoints such as cocaine craving, cocaine dependence symptom
severity, social functioning, and symptoms of depression; however,
because no signiﬁcant treatment effect was found for any of these
exploratory endpoints, details of the assessments are not described.
2.1.1. Contingency management procedure and ﬁnancial compensa-
tion. A contingency management procedure was  used to promote
study retention and decrease the rate of missing data (Petry et al.,
2004). In brief, by attending each scheduled clinic visit and pro-
viding daily data on cocaine use since the previous visit, subjects
earned opportunities to draw plastic chips from a bowl, with each
chip representing a chance to win a non-cash prize ranging in value
from 1 to 100 US dollars. Most chips had no prize value and sim-
ply carried a positive message, such as “good job.” The number of
chips associated with a given prize value varied inversely in pro-
portion to value, with only one $100 prize chip present in the bowl.
The number of allowed draws from the bowl during a clinic visit
increased with the number of consecutive study visits attended,
and it reset to a lower level if a scheduled visit was missed. In addi-
tion, study participants received ﬁnancial compensation for their
time and inconvenience, with the level of compensation deter-
mined by established site practices. At maximum, subjects received
up to $1500 (US) or the equivalent in total compensation.
2.2. Participants
Males and females, 18–60 years of age, who  met DSM-IV criteria
for cocaine dependence as determined by the Structured Clinical
Interview for DSM-IV Axis I Disorders, (First et al., 2002), were
randomized at 17 of the 19 sites that conducted screening. Partici-
pants were required to be treatment-seeking (by self-report), to be
capable of understanding and providing written informed consent,
and to be likely (in the opinion of site investigators) to com-
plete the 12-week treatment period. In addition, participants were
required to have at least one positive on-site urine test for BE dur-
ing screening. Exclusion criteria included: diagnosed dependence
on any psychoactive substance other than cocaine, alcohol, nico-
tine, benzodiazepines or marijuana; alcohol dependence requiring
detoxiﬁcation; ongoing, court-mandated treatment for cocaine
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se; severe psychiatric disorder; serious medical illness; previously
ttempted suicide; pregnancy; and liver enzyme plasma levels ele-
ated to more than 3 times the upper limit of normal. Participants
ere also excluded from randomization if all urine samples tested
ositive for opiates during screening, if they previously participated
n a cocaine vaccine trial (lifetime history), or if they participated in
ny other investigational trial for cocaine dependence treatment in
he 60 days prior to screening. Inclusion and exclusion criteria were
esigned to allow polysubstance abuse (common in the eventual
linical target population) unless there was an unacceptably high
robability of serious adverse events, as was judged to be the case
or comorbid opioid dependence.
.3. Drug treatment
TV-1380 was reconstituted by adding 1 mL  of sterile water for
njection to a vial containing lyophilized material, resulting in a
00 mg  TV-1380/1 mL  buffer formulation containing sodium phos-
hate, mannitol, trehalose and polysorbate 80, with a pH of 7.2.
he placebo solution consisted of sodium phosphate, mannitol, tre-
alose, and polysorbate 80. In order to keep the volume of injection
he same for all participants, subjects who were assigned to the
50 mg  TV-1380 group received 1.5 mL  of 100 mg/mL  solution and
.5 mL  of placebo buffer solution, those assigned to the 300 mg  TV-
380 group received 3 mL  of the 100 mg/mL solution and those
ssigned to the placebo group received 3 mL  of the placebo buffer
olution. The clinical personnel involved in the study, the sponsor
nd the participants were blinded to the study drug identity. An
nblinded pharmacist or healthcare professional who was  inde-
endent of the study team prepared the syringes, covering them
ith transparent green colored tape to mask color differences.
ntramuscular injections were administered once weekly to the
luteus maximus.
.4. Endpoints
The primary efﬁcacy endpoint was abstinence from cocaine
uring the last 3 weeks of the 12-week treatment period. To be
onsidered abstinent, a participant was required to: 1) report no
ocaine use for each day during weeks 10–12; 2) provide at least one
rine sample during each week of the 3-week period; and 3) have
ll urine assay results from the period negative for cocaine metabo-
ites (BE < 150 ng/mL and EME  < 15 ng/mL). The secondary efﬁcacy
ndpoint was the percentage of urine samples in each treatment
roup that were negative for cocaine metabolites (BE < 150 ng/mL
nd EME  < 15 ng/mL) during the last 8 weeks of the 12-week treat-
ent period. For this secondary endpoint, missing samples were
onsidered positive for cocaine metabolites. In addition, there was
ne exploratory endpoint focused on cocaine use: the percentage of
articipants in each group who were abstinent from cocaine during
he last 8 weeks of the treatment period based on daily self-report
f no cocaine use, conﬁrmed by urine sample negativity for cocaine
etabolites throughout the period.
The safety and tolerability of TV-1380 were assessed by eval-
ating AEs, clinical lab examinations, vital signs measurements,
lectrocardiogram (ECG) results, and concomitant medication
sage. Assessments of the development of antibodies against HSA,
ChE and TV-1380 were conducted at baseline and weeks 4, 8, 12
nd 16. Endogenous BChE and AChE activity levels were deter-
ined using a colorimetric method based on the Ellman assay.
V-1380 serum concentrations were measured using a validated
LISA method and the following PK parameters were calculated:
pparent peak serum concentration (Cmax), trough concentration
rior dosing (Cmin) and area under the concentration-time curve
uring a dosing interval (AUCtau). Subjects were categorized as pre-
xisting positive for anti-drug antibodies (ADAs) if there was  anl Dependence 166 (2016) 13–20 15
ADA-positive sample prior to treatment. A subject was  regarded as
exhibiting a treatment-emergent ADA responses if: 1) there was
an ADA-positive sample after but not before treatment or 2) the
subject had ADA-positive samples both before and after treatment,
and the antibody titer increased at least 4-fold.
2.5. Data analysis
The intent-to-treat (ITT) population includes all randomized
participants. The Safety Population includes all randomized par-
ticipants who  received at least one dose of TV-1380 or placebo.
The Efﬁcacy Population includes all randomized participants who
received at least one dose of study drug with the exclusion of one
participant who  was  randomized at two  different sites (this was
detected four weeks into overlapping placebo and 150 mg  TV-1380
treatment, and both treatments were immediately discontinued).
The PK Analysis Population includes all subjects in the ITT popula-
tion who  received at least one dose of study drug and had at least
one analyzable PK blood sample.
Subject demographic and baseline characteristics, including
medical history, prior medications, and ECG ﬁndings were statisti-
cally analyzed using an analysis of variance (ANOVA) for continuous
variables and Pearson’s chi-square or Fisher Exact test for cate-
gorical variables. In the efﬁcacy analysis, the Hochberg’s Step-Up
method for multiple comparisons (Hochberg 1988) in combination
with a hierarchical method between the primary and secondary
endpoint analyses were used to maintain experiment-wise type
1 error of 5%. Logistic regression analysis on the Efﬁcacy Popula-
tion was  used to evaluate the odds of participants being abstinent
during the last 3 weeks of the treatment period between subjects
administered either 150 or 300 mg  TV-1380 compared to placebo.
The analysis was  stratiﬁed by pooled center (centers with less
than 6 patients were pooled together) with the following vari-
ables: treatment group, alcohol dependence or non-dependence,
route of cocaine administration, and positivity or negativity of last
urine sample prior to randomization. The secondary endpoint was
analyzed using analysis of covariance (ANCOVA) on the Efﬁcacy
Population, comparing each of the TV-1380 dose groups to the
placebo group. The model included the same covariates as used
in the primary endpoint analyses and pooled center. Consistent
with the hierarchical method, the statistical analysis plan (SAP) for
the current trial states that the secondary efﬁcacy endpoint will be
tested at an alpha level of 5% only in the case of signiﬁcant ﬁndings
for the primary endpoint. Hence, in the absence of a signiﬁcant ﬁnd-
ing for the primary endpoint, a nominal p-value is reported for the
secondary endpoint but no conclusion is drawn regarding statisti-
cal signiﬁcance (readers may  draw their own conclusions regarding
the likelihood of a chance ﬁnding based on the reported p values).
In addition to the ANCOVA model (pre-speciﬁed in the SAP), a non-
linear over-dispersion binomial regression model was  used for the
secondary endpoint. The exploratory endpoint of the percentage of
subjects abstinent from cocaine during the last 8 weeks of treat-
ment was  analyzed using logistic regression analysis similar to the
primary analysis.
Descriptive statistics were used to summarize reported AEs,
vital signs, ADAs, laboratory assessments, and concomitant medi-
cation use. Absolute values for BChE and AChE activity, change from
baseline activity, and the percentage change from baseline activity
were calculated for each treatment group and time point. TV-1380
PK parameters were derived using non-compartmental analysis. In
cases where the ﬁnal sampling time was  between 162 and 168 h
post-dose, the AUC0-t was  used as an estimation of AUC0-168 or
AUCtau. For proﬁles where all concentrations were below the lower
limit of quantiﬁcation (BLQ < 134 ng/mL), Cmax was reported as BLQ
and AUC0-t was  reported as zero.
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.1. Patient disposition and demographic characteristics
Fig. 1 depicts the disposition of participants during the study.
ubjects were screened but not randomized due to following rea-
ons: 2 for adverse events, 9 subject withdrawals, 44 did not meet
nclusion criteria, 85 met  exclusion criteria, 27 were lost to follow-
p and 7 for other reasons. Of the 382 participants screened, 208
ere randomized and participated in the study from June 2013
o October 2014. A total of 168 participants (80%) completed the
tudy, 81% in the 150 mg  TV-1380 group, 84% in the 300 mg  TV-
380 group, and 77% in the placebo group. Overall, demographic
haracteristics and stratiﬁcation factors were similar across the
reatment groups, with no signiﬁcant differences between groups
nd a similar prevalence of males and black subjects in all three
roups (Table 1). For the vast majority of study participants, alcohol
ependence was not diagnosed, smoking was the primary route of
ocaine administration (77%), the last urine screen prior to random-
zation was positive for cocaine metabolites, and they were from
he United States. Other baseline clinical measures (not reported)
lso did not differ signiﬁcantly between groups.
.2. Analyses of the primary and secondary endpoints
There were no statistically signiﬁcant differences between
he treatment groups for the primary endpoint, abstinence from
ocaine during the last three weeks of treatment. However, analy-
es showed that four subjects (6%) from the 150 mg  TV-1380 group
nd four subjects (6%) from the 300 mg  TV-1380 group met  the
eﬁnition of abstinence from cocaine during the last three weeks
f treatment, whereas no subjects from the placebo group met  thisisposition.
criterion (Table 2). Analysis of the secondary efﬁcacy endpoint (the
percentage of urine samples testing negative for cocaine metabo-
lites during the last 8 weeks of treatment) revealed a TV-1380
dose-dependent increase in negative urines; 4.7%, 8.1% and 14.6%
of urines were negative in the placebo, 150 mg  and 300 mg  TV-1380
groups, respectively (Table 2). The nominal p-value for the 300 mg
dose compared to placebo was 0.027 in the pre-deﬁned ANCOVA
model and 0.0056 in the post-hoc nonlinear over-dispersion bino-
mial regression model. The ANCOVA model did not ﬁt the data well
and, for many subjects, it predicted negative values for the per-
centage of negative urines. The post-hoc model yielded a better ﬁt
and did not predict any negative values. An exploratory analysis
evaluating the percentage of subjects per group with 8 weeks of
abstinence (weeks 5–12) found that one subject (1%) in the 150 mg
TV-1380 group, two subjects (3%) in the 300 mg  TV-1380 group,
and no subjects in the placebo group met  this deﬁnition of absti-
nence from cocaine. However, there were no statistically signiﬁcant
differences between the treatment groups.
3.3. Safety and tolerability
There were seven serious adverse events (SAEs) reported for
ﬁve participants. In the placebo group, alcohol poisoning and sui-
cidal ideation were reported for one participant, and depression
and poly-substance dependence were reported for another. In the
300 mg  TV-1380 group, one case of pneumonia, one cerebrovas-
cular accident (CVA), and once case of musculoskeletal chest pain
were reported for three separate participants. All SAEs were judged
not to be related to the study drug. There were 147 subjects report-
ing at least 1 AE during the study. The observed AEs occurring at
a higher frequency in the TV-1380 groups and for more than one
participant per group are summarized in Table 3. All AEs were mild-
Y. Gilgun-Sherki et al. / Drug and Alcohol Dependence 166 (2016) 13–20 17
Table  1
Patient demographics characteristics and stratiﬁcation factors.
Placebo (n = 69) TV-1380 150 mg/week (n = 70) TV-1380 300 mg/week (n = 69) Total (N = 208)
Demographic Characteristics
Age, years: 47.5 (8.24) 47.2 (8.18) 46.4 (7.05) 47.1 (7.82)
Mean  (SD) [Min, Max] [26.0, 60.0] [26.0, 60.0] [27.0, 58.0] [26.0, 60.0]
Gender, males: n (%) 43 (62) 50 (71) 48 (70) 141 (68)
Race  – –
Black: n (%) 56 (81) 55 (79) 52 (75) 163 (78)
White:  n (%) 10 (14) 13 (19) 10 (14) 33 (16)
Other: n (%) 2 (3) 2 (3) 7 (10) 11 (5)
Missing: n (%) 1 (1) – – –
Ethnicity
Not  Hispanic or Latino: n (%) 64 (93) 64 (91) 61 (88) 189 (91)
Hispanic or Latino: n (%) 5 (7) 6 (9) 8 (12) 19 (9)
Weight, kg: Mean (SD) 86.7 (21.74) 83.6 (14.88) 84.7 (21.68) 85.0 (19.63)
[Min,  Max] [49.4, 146.8] [48.4, 135.2] [42.8, 160.0] [42.8, 160.0]
Height, cm:  Mean (SD) 171.8 (11.42) 173.5 (9.36) 173.5 (9.29) 172.9 (10.05)
[Min,  Max} [137.2, 198.1] [149.9, 190.5] [152.4, 198.1] [137.2, 198.1]
BMI,  kg/m2: Mean (SD) 29.3 (6.47) 28.0 (5.99) 28.1 (7.02) 28.5 (6.50)
[Min,  Max] [18.1, 46.1] [17.8, 50.4] [17.3, 55.4] [17.3, 55.4]
Stratiﬁcation Factors, n (%)
Alcohol dependence
Yes 7 (10) 7 (10) 5 (7) 19 (9)
No  62 (90) 63 (90) 64 (93) 189 (91)
Cocaine route of administration
Smoking 54 (78) 54 (77) 53 (77) 161 (77)
Snorting 15 (22) 16 (23) 16 (23) 47 (23)
Last  urine cocaine screen prior to randomization
Positive 62 (90) 62 (89) 61 (88) 185 (89)
Negative 7 (10) 8 (11) 8 (12) 23 (11)
Country
United States 65 (94) 65 (93) 66 (96) 196 (94)
Spain  4 (6) 5 (7) 3 (4) 12 (6)
Table 2
Effect of TV-1380 on abstinence rates and cocaine use.
Outcome Placebo (n = 66)a TV-1380 150 mg (n = 69) a TV-1380 300 mg (n = 68)a
Primary Endpoint (abstinence
during the last 3 weeks of
treatment)
Abstinent Subjects 0 4 (6%) 4 (6%)
Odds Ratio – 3.66 4.48
95%  Conﬁdence Interval – (0.62, ∞) (0.72, ∞)
p-value – 0.1487 0.1205
Secondary Endpoint (percentage of
planned urine samples that were
negative for cocaine metabolites
during the last 8 weeks of
Arithmetic Mean ± SE 4.7 ± 1.9 8.1 ± 2.7 14.6 ± 3.3
Least  Squares Mean ± SE 5.5 ± 2.7 8.8 ± 3.7 15.5 ± 5.8
Difference in LS Mean (Active minus Placebo) – 3.34 9.96
p-value (Pre-deﬁned ANCOVA model) – 0.3607 0.0268
p-value (Binomial regression model) 0.2546 0.0056
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a Two subjects randomized to placebo and one subject randomized to 300 mg  TV
ifferent sites and was randomized to receive both placebo and 150 mg TV-1380. A
oderate except two severe AEs (alcohol poisoning in the placebo
roup and CVA in the 300 mg  TV-1380 group). No meaningful dif-
erences between the placebo and TV-1380 groups were observed.
here were no notable changes in clinical laboratory parameters,
ital signs or ECG measurements associated with TV-1380 admin-
stration.
One of the 208 study subjects was found to be pre-dose pos-
tive for anti-TV-1380 antibodies, whereas 12 of the 208 were
ound to be pre-dose positive for anti-HSA antibodies. During the
tudy, there was no ADA development in placebo-treated subjects,
owever, 32 of the 69 subjects (46%) in the TV-1380 150 mg  treat-
ent group and 35 of the 70 subjects (50%) in the TV-1380 300 mg
reatment group were observed to have treatment-emergent ADA
esponses. The majority of the response was seen at Week 8 and
asted over the remaining course of treatment. All of these subjects
howed reductions in ADA titers at the 6 month follow-up visit. did not receive treatment. In addition, one subject surreptitiously enrolled at two
ese subjects were excluded from efﬁcacy analyses.
At week 16, the mean percentage changes from baseline in
endogenous BChE levels were +4.8%, −2.0% and +1.4% for the
placebo, 150 mg  and 300 mg  TV-1380 groups, respectively. For
AChE levels, it was +2.4%, +1.0% and −0.3% change from baseline
for the placebo, 150 and 300 mg  TV-1380 groups, respectively. For
those in the 150 and 300 mg  groups with positive ADA, the per-
centage change from baseline to the 6 month follow-up visit was
−1.5% and +5.5% for endogenous BChE levels, and +5.0% and +6.9%
for endogenous AChE levels, respectively.
3.4. Pharmacokinetic evaluations
TV-1380 PK parameters are provided in Table 4. In most cases,
the apparent Cmax was  observed by the ﬁrst sampling time post-
dose for both TV-1380 groups. The mean Cmin, Cmax, and AUCtau
values were similar within each dose group across sampling days
(Weeks 1, 4, 8, and 12), suggesting that accumulation was mini-
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Table 3
Adverse events occurring for more than 1 participant per TV-1380 group and at a higher frequency in TV-1380 groups.
Placebo (n = 67) TV-1380 150 mg  (n = 68) TV-1380 300 mg  (n = 70)
Subjects with at least 1 AE n (%) 42 (63) 54 (79) 51 (73)
Nausea 5 (7) 6 (9) 4 (6)
Diarrhea 2 (3) 4 (6) 3 (4)
Toothache 2 (3) 4 (6) 0
Vomiting 1 (1) 3 (4) 4 (6)
Abdominal pain 0 1 (1) 2 (3)
Abdominal pain upper 0 0 2 (3)
Fatigue 2 (3) 3 (4) 2 (3)
Inﬂuenza like illness 1 (1) 0 2 (3)
Injection site pain 1 (1) 2 (3) 3 (4)
Injection site pruritus 1 (1) 0 2 (3)
Chest  pain 0 0 2 (3)
Nasopharyngitis 7 (10) 8 (12) 9 (13)
Inﬂuenza 2 (3) 3 (4) 3 (4)
Urinary tract infection 1 (1) 0 2 (3)
Pneumonia 0 2 (3) 0
Blood cholesterol increased 1 (1) 2 (3) 0
Blood urine present 1 (1) 0 2 (3)
Blood  creatine phosphokinase increased 1 (1) 5 (7) 3 (4)
Creatinine urine increased 1 (1) 2 (3) 3 (4)
Gamma-glutamyltransferase increased 0 1 (1) 2 (3)
Protein urine present 0 0 3 (4)
Weight increased 0 2 (3) 1 (1)
Arthritis 0 0 2 (3)
Back  pain 3 (4) 4 (6) 1 (1)
Muscle spasms 1 (1) 0 3 (4)
Musculoskeletal chest pain 0 3 (4) 0
Myalgia 0 1 (1) 2 (3)
Pain  in extremity 0 0 2 (3)
Headache 3 (4) 4 (6) 2 (3)
Anxiety 1 (1) 1 (1) 3 (4)
Insomnia 1 (1) 1 (1) 3 (4)
Dysmenorrhea 1 (1) 2 (3) 2 (3)
Nasal  congestion 0 1 (1) 2 (3)
Hypertension 1 (1) 3 (4) 3 (4)
Table 4
TV-1380 pharmacokinetic parameters in subjects following weekly IM injections of TV-1380.
Dose PK Parametera Week 1 Week 4 Week 8 Week 12
150 mg Cmax (ng/mL) 1181.6 1461.1 1363.3 1573.1
tmax (h) 47.28 47.18 47.94 44.57
Cmin (ng/mL) NA 308.9 410.7 520.4
AUC0-t (ng h/mL) 96438.3 132311 135680 103347
AUC0-168 or AUC (ng h/mL) 128683 126625 131851 NC
Estimated AUC0-168 or AUC (ng h/mL) 117830 151142 149754 155109
300  mg Cmax (ng/mL) 2361.8 2824.8 2610.7 2788.1
tmax (h) 48.02 47.43 47.89 45.60
Cmin (ng/mL) NA 660.7 826.7 899.6
AUC0-t (ng h/mL) 192432 257007 267667 212599
AUC0-168 or AUC (ng h/mL) 225045 235306 247471 160072
Estimated AUC0-168 or AUC (ng h/mL) 201619 284579 274779 264019
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aa PK parameters included: apparent peak serum concentration (Cmax), time to achi
ime  curve from time 0 to the time of the last quantiﬁable serum drug concentration
r AUC); Median reported for tmax; NA: Not applicable; NC: Not calculable.
al  and steady state concentration levels were attained. Exposure
arameters (Cmax, AUC0-t, AUC 0–168, and AUCtau) following 150
nd 300 mg  dose levels indicate that the change in exposure was
pproximately dose-proportional.
. Discussion
Although weekly intramuscular injections of TV-1380 did not
igniﬁcantly impact abstinence rates during the last three weeks
f treatment (the primary efﬁcacy endpoint in this study), the
on-signiﬁcant increase in abstinence rates and the dose-related
ncrease in the percentage of negative urines during the last two
onths of treatment (signiﬁcant for 300 mg  TV-1380 vs. placebo)
re encouraging. The 300 mg  dose of TV-1380 has been shownax (Tmax), trough concentration prior to dosing (Cmin), area under the concentration-
0-t), and area under the concentration-time curve during a dosing interval (AUC0-168
to signiﬁcantly decrease the half-life of cocaine and decrease the
duration of the reported “high” (as well as other subjective effects)
following intravenous cocaine infusions in healthy, nondependent
cocaine users (Shram et al., 2015). The increased clearance of
cocaine and attenuated subjective effects were accompanied by
decreased visual analog scale scoring for the statement “I would
take this drug again” (with a score of 100 = “deﬁnitely so” and
0 = “deﬁnitely not”). These human laboratory ﬁndings are consis-
tent with the apparent decrease in cocaine use following TV-1380
treatment in the current study. However, an effective pharma-
cotherapy for cocaine dependence will almost certainly need to
produce greater reductions in cocaine use.
While the present data argue for evaluation of higher doses of
TV-1380 (or more frequent administration of the 300 mg  dose), this
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ay  not be possible in the context of developing a viable product
or the treatment of cocaine dependence. It appears reasonable to
ypothesize that higher plasma levels of TV-1380 would produce
ven faster clearance of cocaine, more robust blunting of cocaine’s
ubjective effects, and greater reductions in cocaine use. However,
onsideration must be given to the cost of goods (material, labor,
nd overhead costs associated with bringing a product to patients)
nd the fact that payers have ﬁnite resources. Such considerations
ontributed to the selection of 300 mg  as a dose limit in the current
nd previous TV-1380 studies. As for more frequent administra-
ion, an unpublished survey of treatment providers (conducted
uring protocol development) indicated that an injection product
or cocaine dependence treatment would be unacceptable if it had
o be administered more frequently than once weekly.
Although the continued development of TV-1380 appears
nlikely, its promising clinical proﬁle should embolden efforts to
evelop new enzyme products that are capable of delivering greater
atabolic activity. Compared to the enzyme component of TV-1380,
nzymes with greater catalytic efﬁciency for cocaine hydrolysis
Zheng et al., 2013) and longer duration of action (Fang et al., 2014)
ave already been engineered from human BChE. Further research
ay  yield further improvements. Recent advances in carrier pro-
ein technology may  also prove beneﬁcial. For example, use of the Fc
egion of human IgG1 as a carrier protein has been shown to protect
gainst lysosomal degradation, resulting in fusion protein product
alf-lives of up to 17 days (Baldo, 2015). Thus, the recent synthesis
f a functional IgG1 Fc-fused cocaine hydrolase (Chen et al., 2016) is
specially encouraging. Regardless of the enzymes and carrier pro-
eins selected, achieving cost efﬁciency in large-scale production
ill be important for product viability. In addition, although ADA
ormation was associated with no apparent clinical consequence
n the current study, the high percentage of subjects who exhib-
ted such a response cautions that antigenicity will be an important
actor to consider in next-generation products.
In summary, the clinical proﬁle of TV-1380 appears sufﬁciently
ositive to justify efforts toward development of improved cocaine
atabolic enzyme products. Such efforts may  lead to regulatory
pproval of the ﬁrst effective pharmacotherapy for cocaine depen-
ence.
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